Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion

Research output: Contribution to journalArticle

Abstract

Background and Objectives: Peritoneal mesothelioma (PM) is a rare disease, with a poor prognosis. We decided to prospectively evaluate the prognostic impact of aggressive surgery followed by intraperitoneal chemotherapy with local hyperthermia. Patients and Methods: In this prospective study, 19 patients with PM were treated by cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Mean follow-up was 27 months (range: 1-65). Fifteen (68%) patients had malignant disease, two had well-differentiated papillary mesothelioma, and two had multicystic PM. Thirteen (65%) patients received preoperative chemotherapy. Fifteen cases (75%) underwent optimal cytoreduction (residual disease

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalJournal of Surgical Oncology
Volume83
Issue number3
DOIs
Publication statusPublished - Jul 1 2003

Keywords

  • Peritioneal chemotherapy
  • Peritoneal mesothelioma
  • Peritonectomy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion'. Together they form a unique fingerprint.

  • Cite this